Bradycardia in the Emergency Department: High-Yield MRCEM SBA Practice Questions Explained

Bradycardia is one of those presentations that separates the confident ED clinician from the hesitant one. A rate below 60 beats per minute is common, and the vast majority of patients require no intervention whatsoever. But within that same cohort sits the patient in complete heart block, haemodynamically unstable, who needs atropine and a pacing wire within minutes. The MRCEM SBA exam exploits precisely this diagnostic and management breadth: questions test whether candidates can risk-stratify rapidly, apply the correct algorithm, select the right drug dose, and know when to escalate. This article works through the core science, the Resuscitation Council UK 2025 adult bradyarrhythmia algorithm, and a set of high-yield MRCEM SBA practice questions with detailed explanations.

Clinical Context and Why This Topic Matters in the ED

Symptomatic bradycardia requiring active intervention is more common in older patients with underlying structural or ischaemic heart disease, but drug toxicity and vagally mediated bradycardia present across all age groups. In UK Emergency Departments, the two most clinically urgent scenarios are AV conduction block complicating inferior ST-elevation myocardial infarction and drug-induced bradycardia from beta-blocker or rate-limiting calcium channel blocker toxicity. Both carry immediate mortality risk if mismanaged.

The National Institute for Health and Care Excellence references bradyarrhythmia management within the context of acute coronary syndromes and cardiac arrhythmia guidelines. The Resuscitation Council UK 2025 algorithm, which supersedes the previous 2021 iteration, remains the primary governance document for acute bradycardia management in UK Emergency Departments and is directly examinable in the MRCEM SBA exam.

Pathophysiology: From SA Node to Escape Rhythm

Normal cardiac automaticity originates in the sinoatrial (SA) node, which fires at 60 to 100 bpm under the influence of the autonomic nervous system. Parasympathetic tone via the vagus nerve slows the SA node; sympathetic stimulation accelerates it. If SA node function is impaired or conduction through the AV node and His-Purkinje system is interrupted, subsidiary pacemakers take over at progressively slower and less reliable rates: the AV junctional tissue fires at 40 to 60 bpm, and the ventricular escape (His-Purkinje) pacemaker at 20 to 40 bpm.

This hierarchy has direct clinical relevance. A junctional escape rhythm produces a narrow QRS complex at 40 to 60 bpm and is relatively stable. A ventricular escape rhythm produces a broad QRS complex at 20 to 40 bpm, is inherently unstable, and heralds imminent asystole if not treated. Candidates sitting MRCEM SBA practice questions on this topic must recognise that QRS width in the setting of bradycardia conveys prognostic and management information, not merely diagnostic label.

AV Block Classification

AV block is classified into three degrees, each with distinct ECG appearances and management implications.

• First-degree AV block: PR interval greater than 200 milliseconds, every P wave conducts. Benign in isolation. No treatment required.
• Second-degree AV block, Mobitz type I (Wenckebach): Progressive PR prolongation culminating in a dropped beat. The block is at the level of the AV node. Usually benign, responds to atropine if symptomatic, and is commonly seen in inferior MI.
• Second-degree AV block, Mobitz type II: Fixed PR interval with intermittent non-conducted P waves. The block is infranodal (His-Purkinje level). Carries risk of progression to complete block. Atropine is less reliable and urgent pacing is often required.
• Third-degree (complete) AV block: Complete dissociation of atrial and ventricular activity. The QRS morphology reflects the level of the escape pacemaker. Wide-complex escape rhythms at slow rates represent the highest-risk scenario and mandate urgent transvenous pacing.

ED Assessment and Management: Applying the Resus Council UK 2025 Algorithm

The Resuscitation Council UK 2025 adult bradyarrhythmia algorithm begins with a simultaneous approach: identify the patient is bradycardic, secure intravenous access, attach continuous monitoring, obtain a 12-lead ECG, and provide supplemental oxygen if the patient is hypoxic. Reversible causes, the 4 Hs (hypoxia, hyperkalaemia, hypothermia, hydrogen ion excess) and 4 Ts (tension pneumothorax, tamponade, toxins, thrombosis), should be considered and treated in parallel.

Risk Stratification: Adverse Features

The pivotal decision in the algorithm is whether adverse features are present. The four adverse features are:

1. Shock (systolic BP below 90 mmHg, pallor, diaphoresis, confusion)
2. Syncope
3. Myocardial ischaemia (ischaemic chest pain, ischaemic ECG changes)
4. Heart failure (acute pulmonary oedema)

If any adverse feature is present, atropine 500 micrograms IV is administered immediately and repeated every three to five minutes to a maximum total dose of 3 mg. This is a high-frequency MRCEM SBA exam question stem: candidates are asked to identify the correct first-line agent, dose, and maximum dose. Common distractors include atropine 1 mg (the old adult ALS cardiac arrest dose, not the bradycardia dose), and isoproterenol, which is not part of standard UK practice.

When Atropine Is Unlikely to Work

Atropine acts by blocking vagal muscarinic receptors at the SA and AV nodes. It is therefore most effective in vagally mediated bradycardia and least effective when the block is infranodal (Mobitz type II, complete heart block with broad-complex escape, post-cardiac-transplant patients who have no vagal innervation). In these cases the algorithm directs clinicians to second-line agents and pacing without delay.

Second-Line Pharmacological Options

If atropine fails or is unlikely to work, second-line agents include isoprenaline (isoproterenol) 5 micrograms per minute IV infusion (as a bridge to pacing), adrenaline 2 to 10 micrograms per minute IV infusion, and specific antidotes in toxicological causes. For beta-blocker toxicity, high-dose insulin euglycaemic therapy, glucagon, and intravenous lipid emulsion are relevant; for digoxin toxicity, digoxin-specific antibody fragments (DigiFab) are the definitive treatment. The British National Formulary provides current dosing guidance for all of these agents.

Transcutaneous and Transvenous Pacing

External transcutaneous pacing is the most rapidly available pacing modality in the ED and should be initiated in any patient with adverse features where atropine has failed or is unlikely to work, while preparations are made for transvenous pacing. Transcutaneous pacing is painful and should be provided with procedural analgesia and sedation. Transvenous pacing, arranged with cardiology, is the definitive bridge to permanent pacemaker insertion for patients with high-degree block requiring ongoing support.

How the MRCEM SBA Exam Tests Bradycardia

Bradycardia is a topic with rich SBA potential because it demands integration of ECG interpretation, pharmacology, algorithm application, and clinical reasoning within a single question. Candidates preparing MRCEM SBA revision should expect question stems that present a clinical vignette with a brief ECG description and ask: what is the immediate management, what is the correct drug and dose, which ECG finding represents the highest-risk rhythm, or what is the most appropriate disposition?

The Royal College of Emergency Medicine curriculum (2021, updated) maps bradycardia to the Cardiovascular Emergencies domain and expects trainees to demonstrate competence in ECG interpretation, adverse feature recognition, algorithm-guided pharmacological management, and safe escalation to pacing. Questions frequently include distractors that test knowledge of which drug is not appropriate (for example, atropine in complete heart block with broad-complex escape, where it buys little and delays definitive treatment) or which scenario requires pacing rather than pharmacology alone.

Sample High-Yield MRCEM SBA Practice Questions

Question 1

A 72-year-old woman presents with pre-syncope and a heart rate of 38 bpm. Her BP is 84/50 mmHg. The 12-lead ECG shows P waves occurring at 80 bpm with no consistent relationship to QRS complexes, which are broad at 160 ms. What is the most appropriate immediate management?

A. Atropine 500 micrograms IV
B. Atropine 3 mg IV bolus
C. Atropine 500 micrograms IV and prepare for transcutaneous pacing
D. Transcutaneous pacing, with analgesia and sedation
E. Metoprolol 5 mg IV

Best answer: D. This ECG describes complete (third-degree) AV block with a broad-complex ventricular escape rhythm. This represents infranodal block. Atropine has minimal efficacy at this level, and while option C acknowledges this partial reality, the correct answer in the context of haemodynamic compromise (adverse features: shock and syncope) is to proceed directly to transcutaneous pacing, which is the algorithm-directed action when atropine is unlikely to work. Option B (3 mg bolus) is never appropriate as a single dose. Option E (metoprolol) would be catastrophic.

Question 2

A 58-year-old man presents with an inferior STEMI. During the resuscitation room assessment his heart rate drops to 44 bpm with a BP of 96/60 mmHg and he reports dizziness. The ECG shows progressive PR prolongation followed by a dropped beat, repeating in a cyclical pattern. What is the most appropriate immediate pharmacological treatment?

A. Isoprenaline 5 micrograms/min IV infusion
B. Atropine 500 micrograms IV
C. Digoxin 500 micrograms IV
D. Adenosine 6 mg IV
E. Amiodarone 300 mg IV

Best answer: B. The ECG description is classic Mobitz type I (Wenckebach) second-degree AV block, which in the context of inferior STEMI reflects ischaemia of the AV node (supplied predominantly by the right coronary artery). This is a nodal-level block and responds to atropine. Adverse features (dizziness, borderline hypotension) are present. Atropine 500 micrograms IV is first-line. Isoprenaline is a second-line agent if atropine fails. Digoxin, adenosine, and amiodarone are all contraindicated here.

Revision Pearls: High-Yield Facts for MRCEM SBA Exam Preparation

1. The Resus Council UK 2025 algorithm uses adverse features, not heart rate threshold, to determine urgency of treatment.
2. Atropine dose in bradycardia is 500 micrograms IV, repeated every 3 to 5 minutes to a maximum of 3 mg. This differs from the cardiac arrest dose.
3. Broad-complex escape rhythms in complete heart block reflect His-Purkinje pacemaker activity, are inherently unstable, and predict higher risk of asystole than narrow-complex junctional escape.
4. Atropine is relatively contraindicated in Mobitz type II and complete heart block with broad-complex escape because it may paradoxically worsen infranodal block by accelerating the atrial rate without improving ventricular conduction.
5. Inferior STEMI causes Wenckebach (Mobitz I) via RCA ischaemia of the AV node. Anterior STEMI causes Mobitz II or complete heart block via septal branch ischaemia of the His-Purkinje system, which is a higher-risk scenario.
6. Post-cardiac-transplant patients have no vagal innervation: atropine will not work. Proceed directly to isoprenaline or pacing.
7. Lyme disease is an important reversible cause of complete heart block in the correct epidemiological context (endemic areas, tick exposure history) and is a favourite MRCEM SBA clinical scenario.
8. Digoxin toxicity requires digoxin-specific antibody fragments (DigiFab), not atropine as the definitive treatment. The BNF guidance on digoxin toxicity should be reviewed directly.

Common Pitfalls: Where Candidates Lose Marks

• Confusing the atropine dose for bradycardia (500 micrograms) with the atropine dose in asystolic cardiac arrest (3 mg, no longer recommended in current ALS algorithms, having been removed).
• Selecting atropine as best answer for complete heart block with wide-complex escape and adverse features, where pacing is the correct priority.
• Failing to recognise that Mobitz type II block is infranodal and carries a higher risk of progression to complete block than Mobitz type I.
• Missing drug history as a reversible cause: beta-blockers and verapamil are common culprits in UK practice and often buried in the question stem.
• Overlooking hyperkalaemia as a cause of progressive bradycardia and conduction abnormality, particularly in patients with renal impairment or on potassium-sparing agents.
• Misidentifying the escape rhythm: narrow complex at 50 bpm is junctional (relatively stable); broad complex at 30 bpm is ventricular (unstable, pace urgently).

How EM Learning Centre Supports Your MRCEM Single Best Answer Revision

Bradycardia management integrates ECG interpretation, pharmacology, algorithm recall, and clinical risk stratification. These are exactly the cognitive skills the MRCEM SBA exam is designed to probe. Working through structured, high-quality MRCEM SBA practice questions with detailed explanations is the most effective way to consolidate this material and identify gaps before the exam.

The MRCEM Single Best Answer revision course at EM Learning Centre covers the full breadth of the RCEM curriculum, including cardiovascular emergencies, toxicology, resuscitation, and the clinical scenarios most commonly tested in the exam. Each question is accompanied by a full explanation grounded in UK guidelines, helping you not just select the right answer but understand the reasoning behind it. Whether you are building a systematic revision plan or targeting specific weak areas, the EM Learning Centre question bank provides the depth and clinical accuracy that this exam demands.

References

1. Resuscitation Council UK. Adult bradyarrhythmia algorithm 2025. Resuscitation Council UK.
2. National Institute for Health and Care Excellence. Arrhythmia guidelines and clinical knowledge summaries. NICE.
3. British National Formulary. Digoxin-specific antibody fragments; isoprenaline; atropine dosing. BNF via NICE.
4. Royal College of Emergency Medicine. Emergency Medicine Curriculum 2021 (updated). Cardiovascular Emergencies domain. RCEM.
5. The BMJ. Bradycardia: assessment and management in the acute setting. The BMJ.